1. Introduction {#sec1}
===============

Stenosis of the aortic valve (AS) is a common clinical finding, especially in elderly patients. In population studies, the prevalence of moderate or severe AS has been reported as about 3% of subjects ≥75 years by Nkomo et al. \[[@B1]\] and Lindroos et al. \[[@B2]\] reported that AS prevalence was 2.9% among people aged 75 to 85 years (aortic valve opening area (AVA) ≤0.8 cm^2^) or 4.8% (AVA ≤1.2 cm^2^) depending on the AVA. Prevalence of severe AS increased to 5.9%, and the 3-year mortality was about 40% in a population aged ≥80 years \[[@B3]\]. Studies also showed that AS was complicated by various cardiac and noncardiac comorbidities in elderly populations \[[@B4], [@B5]\]. Previous studies demonstrated the relevant prognostic impact of many factors including low systolic blood pressure \[[@B6]\], depressed systemic arterial compliance \[[@B7]\], left ventricular ejection fraction and mean transvalvular gradient \[[@B8]\], and the outcome with multiple comorbidities and cardiac risk factors was poor in AS patients undergoing surgical valve replacement \[[@B9]\].

Comprehensive epidemiological data about clinical characteristics of patients with valvular heart disease were described in the *Euro Heart Survey on Valvular heart disease* \[[@B10]\]. It is known that common origins existed in the pathophysiology of AS and coronary heart disease \[[@B11], [@B12]\], and some dissimilarities of pathophysiology were also found between the two diseases \[[@B13]\]. Boudoulas et al. demonstrated a high incidence of coronary atherosclerosis in patients with severe AS undergoing surgical aortic valve replacement \[[@B14]\]. Aronow et al. investigated the impact of several cardiovascular comorbidities on mild AS in a retrospective analysis including 180 patients aged ≥60 years and reported male gender, cigarette smoking, systemic hypertension, diabetes mellitus, high low-density lipoprotein cholesterol (LDL-C), and low high-density lipoprotein cholesterol (HDL-C) were associated with fast progression of AS \[[@B15]\]. However, data regarding the impact of cardiac comorbidities and cardiovascular risk factors on the progression of the mean transaortic valve pressure gradient (*P* ~mean~) in patients with moderate or severe AS remain scarce in the literature until now. In this context, especially the role of LDL-C and impact of statin therapy on aortic valve calcification have become the subject of controversial debates \[[@B16]--[@B18]\]. The European Society of Cardiology guidelines on the diagnosis and therapy of valvular heart diseases list rapid progression of AS assessed by echocardiography as a prognostic indicator justifying early aortic valve replacement in asymptomatic patients, but also fall short in providing any potential pathophysiological or mechanistic insights \[[@B19]\]. Therefore, we investigated potential associations between the progression of AS assessed by *P* ~mean~ from serial transthoracic echocardiography and the number of cardiac comorbidities and risk factors in patients with moderate or severe AS in the current study.

2. Methods {#sec2}
==========

2.1. Study Population and Protocol {#sec2.1}
----------------------------------

Adult patients who were diagnosed for acquired moderate or severe AS at final echocardiography and underwent at least two transthoracic echocardiography examinations covering a time interval of one year or more between April 2006 and February 2016 in our department were included in this study. All patients underwent physical examination, transthoracic echocardiography by an experienced examiner, and routine blood testing. Furthermore, blood pressure, body mass index, and medical history at baseline were obtained. Patients were divided into two groups according to the average *P* ~mean~ progression of the cohort (4.52 mmHg/year)---slow progression group: annual *P* ~mean~ progression \<5 mmHg/year and fast progression group: annual *P* ~mean~ progression ≥5 mmHg/year.

We then compared the prevalence of eight known cardiac comorbidities and risk factors (hypertension, diabetes, coronary heart disease, peripheral artery occlusive disease, cerebrovascular disease, renal dysfunction, body mass index (BMI) higher than 30 kg/m^2^, and history of smoking) between the two groups. Furthermore, several laboratory values such as LDL-C, HDL-C, hemoglobin A1c (HbA1c), hemoglobin, creatinine, and C-reactive protein (CRP) were compared between the two groups.

2.2. Echocardiographic Measurements {#sec2.2}
-----------------------------------

A complete echocardiographic examination was performed at baseline and follow-up using Vingmed Vivid 7 or E9 (General Electric, Horten, Norway). Standard measurements were performed according to the ASE guidelines \[[@B12]\]. LV ejection fraction was measured using the biplane Simpson method in the apical 4- and 2-chamber views. The diagnosis and classification of AS were performed according to EAE/ASE recommendations \[[@B13]\]. The outer edge of the AS jet velocity curve in continuous-wave Doppler imaging was traced to obtain maximum AS jet velocity and maximal and mean transaortic pressure gradients (*P* ~max~ and *P* ~mean~).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Statistical analysis was performed using SPSS V 24 (IBM Corp. Armonk, NY, United States). Continuous variables are presented as mean ± standard deviation (SD). Continuous variables of demographic, disease, and echocardiographic characteristics between groups (i.e., nonprogression vs. progression; male vs. female; \<80 years vs. ≥80 years) were, respectively, compared using unpaired Student\'s *t*-test. Categorical variables were expressed as percentages, and differences between groups were compared using a chi-squared test or Fisher\'s exact test, as appropriate. Multivariable logistic regression analysis was conducted to identify independent determinants of faster progression in *P* ~mean~ (≥5 mmHg/year) in this cohort, separately adjusted for age, sex, age and sex, as well as age, sex, and left ventricular ejection fraction (LVEF). Odds ratio (OR) with 95% confidence interval (CI) was used to assess the independent determinants. A two-tailed *P* \< 0.05 was used to indicate statistical significance.

3. Results {#sec3}
==========

A total of 402 consecutive patients (mean age: 78 ± 9.4 years at follow-up echocardiography, 58% males) were included in this study. There are no rheumatic valve disease in this cohort. The average number of cardiac comorbidities and risk factors in the cohort was 3.1 ± 1.6. [Table 1](#tab1){ref-type="table"} shows clinical characteristics of the total cohort at baseline.

As shown in [Table 2](#tab2){ref-type="table"}, prevalence of coronary artery disease and history of myocardial infarction at baseline was significantly lower in the fast progression group than in the slow progression group (both *P* \< 0.05). In addition, there was a trend for lower prevalence of peripheral vascular disease and renal dysfunction at baseline in the fast progression group compared to the slow progression group (*P*=0.08 and 0.09). At follow-up echocardiography, besides lower prevalence of coronary artery disease and history of myocardial infarction, incidence of diabetes was also lower in the fast progression group as compared to the slow progression group. Annual progression in AV *V* ~max~ and AVA VTI were also slow as *P* ~mean~ in the slow progression group as compared to the fast progression group. Moreover, patients in the slow progression group of *P* ~mean~ had significantly more overall cardiac comorbidities and risk factors as compared to the fast progression group (3.3 ± 1.5 vs. 2.9 ± 1.7; *P*=0.036). Both LDL-C and HDL-C values were considerably higher, whereas CRP values were lower in the fast progression group as compared to the slow progression group ([Table 3](#tab3){ref-type="table"}). Percent of patients treated with statins at the time of follow-up echocardiography was similar (fast progression: 55% vs. slow progression: 61.1%; *P*=0.270).

Echocardiographic characteristics of the two groups at baseline and follow-up are shown in [Table 4](#tab4){ref-type="table"}. Baseline parameters were largely similar between slow and fast progression groups except lower LVEF and maximal transaortic velocity (*V* ~max~) values in the slow progression group than in the fast progression group. Left ventricular septal (IVSd) and posterior wall thickness (LVPWd), LVEF, AV *V* ~max~, AV *P* ~max~, and AV *P* ~mean~ were significantly higher while aortic valve area calculated by the velocity time integral (AVA VTI) value was significantly lower in the fast progression group than in the slow progression group at follow-up echocardiography. Compared to baseline values, LVPWd, LVEF, and AVA VTI were reduced, while left atrial diameter, AV *V* ~max~, AV *P* ~max~, and AV *P* ~mean~ were increased in the slow progression group. AVA VTI was significantly reduced, while AV *V* ~max~, AV *P* ~max~, and AV *P* ~mean~ were significantly increased in the fast progression group.

Odds ratio of cardiac comorbidities and risk factors and laboratory parameters at baseline associated with fast *P* ~mean~ progression are shown in [Table 5](#tab5){ref-type="table"}. Univariable logistic regression analysis showed that higher LVEF, lower prevalence of coronary heart disease and myocardial infarction, lower number of comorbidities, higher LDL-C, and HDL-C values were associated with a fast *P* ~mean~ progression over time. After adjustment for age, sex, and LVEF, coronary heart disease, history of myocardial infarction, the number of comorbidities, and LDL-C at baseline remained as independent risk factors associated with *P* ~mean~ progression.

Supplementary Tables [1](#supplementary-material-1){ref-type="supplementary-material"} and [2](#supplementary-material-1){ref-type="supplementary-material"} demonstrate the associations between cardiac comorbidities and risk factors at baseline and follow-up as well as laboratory parameters and fast *P* ~mean~ progression, after adjustment for age, sex, and age plus sex, respectively. Diabetes at follow-up, coronary heart disease, and history of myocardial infarction at baseline and follow-up remained as risk factors of slow progression of *P* ~mean~, and absence of these factors serve as factors indicating a fast progression of *P* ~mean~. Higher average number of comorbidities and lower values of LDL-C and HDL-C remained as risk factors of slow progression of *P* ~mean~ after adjusted for age and sex.

4. Discussion {#sec4}
=============

This retrospective study reveals a context between progressions of the mean transaortic valve pressure gradient (*P* ~mean~) in patients with AS and the prevalence of cardiac comorbidities and risk factors. Based on the study findings, *P* ~mean~ progress is considerably slower in patients with a higher prevalence of cardiac comorbidities and risk factors as compared to those with less prevalence of these factors. Under closer examination, our results indicate that prevalence of coronary heart disease might indeed be the comorbidity with the highest impact on *P* ~mean~ progression, but also other comorbidities such as renal dysfunction and peripheral artery occlusive disease tended to be less common in aortic stenosis patients with fast *P* ~mean~ progression.

The underlying reasons for above finding might be multiple. We speculate that myocardial infarction with subsequent cardiac fibrosis could lead to the inability of building up the pressure within left ventricle, which would be responsible for reduced *P* ~mean~. Consequently, a relative lower LVEF might also be associated with slower progression of *P* ~mean~ ([Table 4](#tab4){ref-type="table"}). Although LVEF at baseline and at follow-up was statistically lower in the slow progression group than in the fast progression group (*P*=0.02 and *P*=0.002), the difference is rather negligible: 2.9% at baseline and 3.8% at follow-up, and the mean EF value was above 50% at both the slow and fast progression groups. Moreover, the prevalence of LVEF\<50% at baseline was 18.7% in the slow progression group and 14.3% in the fast progression group (*P*=0.260), Therefore, it is unlikely that the *P* ~mean~ progression difference was affected by the LVEF values in this study.

No relevant differences were found regarding obesity, hypertension, or nicotine abuse. These results fit to recently published findings indicating a relevant prevalence of coronary artery disease in respective cohorts with aortic stenosis \[[@B20]\]. In contrast to the results from our current study, Rosenhek et al. reported a faster increase in aortic stenosis progression in patients with coronary artery disease \[[@B21]\]. However, this study investigated a cohort with mild and moderate aortic stenosis with patients considerably younger than those in our study, whereas our study population included older patients on average with moderate and severe stenosis.

As aortic stenosis and coronary heart disease might share some pathophysiological background \[[@B11], [@B12]\], they might also share similar cardiac comorbidities and risk factors \[[@B22]\]. In our study, almost half of the aortic stenosis patients had coronary artery disease, but there was no correlation between a higher incidence of coronary heart disease and faster progress of *P* ~mean~. Nevertheless, we found a slower progression of *P* ~mean~ in patients with coronary heart disease as well as in patients with other cardiac comorbidities and risk factors, independent of age, sex, and LVEF. Reduced myocardial contracting power and enhance myocardial fibrosis, reduced myocardial microcirculation, and myocardial-vascular incompetence might be responsible for the observe phenomenon. However, these cannot be verified on the basis of the current data.

In our cohort, patients with fast progress of *P* ~mean~ had higher levels of LDL-C, independent of age, sex, and LVEF. In line with these findings, former studies also revealed higher values of LDL-C to be a risk factor for AS \[[@B23]\] although no benefit from statin therapy on valve function and calcification could be found so far \[[@B24], [@B25]\]. Paradoxically, LDL-C was an independent risk factor for faster progress of *P* ~mean~ in our cohort in the context of similar statins application between the two groups, whereas prevalence of coronary artery disease was higher in the slow progression group. This finding is compatible with former studies showing no impact of statins on AS progression \[[@B25], [@B26]\]. Recently, Thaigo et al. presented a review showing lower values of *P* ~mean~ in patients who were under statin therapy, but they also agree the analyzed studies did not have high quality and concluded that the role of statin therapy in AS remained uncertain \[[@B27]\]. CRP values were also high in the slow progression group indicating increased inflammatory stress in these patients; this could be fairly explained by the increased inflammation status and higher comorbidities in these patients.

It is to note that the diagnosis of definite bicuspid aortic valve was difficult based on transthoracic echocardiography imaging, we thus could not define the impact of bicuspid valve on the *P* ~mean~ progression in this patient cohort.

5. Conclusions {#sec5}
==============

The results of the current study imply that patients with moderate or severe aortic stenosis and a high prevalence of cardiac comorbidities and risk factors, especially history of myocardial infarction and coronary heart disease, diabetes, generally show slower progression of the mean aortic valve pressure gradient compared to patients with a low prevalence of cardiac comorbidities and risk factors. Higher levels of LDL-C are a risk factor for fast progression of *P* ~mean~, while higher CRP is linked with slow *P* ~mean~ progression, indicating a strong correlation between prevalence of cardiac comorbidities and risk factors and inflammation stress. Future studies are warranted to explore the outcome differences between aortic stenosis patients with slow and fast *P* ~mean~ progression.
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Supplementary Materials {#supplementary-material-1}
=======================

###### 

Supplementary tables 1 and 2 demonstrate the associations between cardiac comorbidities and risk factors at baseline and follow-up as well as laboratory parameters and fast *P* ~mean~ progression, after adjustment for age, sex, and age plus sex, respectively. Diabetes at follow-up, coronary heart disease, and history of myocardial infarction at baseline and follow-up remained as risk factor of slow progression of *P* ~mean~ and absence of these factors serve as factors indicating a fast progression of *P* ~mean~. Higher average number of comorbidities and lower values of LDL-C and HDL-C remained as risk factors of slow progression of *P* ~mean~ after adjusted for age and sex.

###### 

Click here for additional data file.

###### 

Characteristics of the cohort at baseline.

                                            Total cohort
  ----------------------------------------- ---------------
  Number                                    402
  Male gender (*n* (%))                     233 (58)
  Age (years)                               74.1 ± 9.8
  BMI (kg/m^2^)                             28.1 ± 5.0
  History of smoking (%)                    36.3
  Diabetes (%)                              35.8
  Coronary heart disease (%)                43.8
  Myocardial infarction (%)                 22.0
  Hypertension (%)                          87.1
  Renal dysfunction (%)                     53.3
  Peripheral artery occlusive disease (%)   23.1
  Cerebrovascular disease (%)               14.7
  Echo LVEF (%)                             53.8 ± 11.5
  Echo *P* ~mean~ (mmHg)                    25.01 ± 14.48

BMI, body mass index; LVEF, left ventricular ejection fraction; *P* ~mean~, mean transaortic pressure gradient.

###### 

Comorbidities of patients with slow or fast progression of mean transaortic pressure gradient at baseline and follow-up echocardiography.

                                        Total cohort   Slow progression (*P* ~mean~ \< 5 mmHg/year)   Fast Progression (*P* ~mean~ ≥ 5 mmHg/year)   *P* value                
  ------------------------------------- -------------- ---------------------------------------------- --------------------------------------------- ----------- ----- ------ -----------
  *Sex*                                                                                                                                                                      0.98
  Male                                  233            58.0                                           152                                           58.0        81    57.9    
  Female                                169            42.0                                           110                                           42.0        59    42.1    
  *Comorbidities at baseline*                                                                                                                                                 
  BMI≥30 Kg/m^2^                        89             29.4                                           55                                            28.1        34    31.8   0.51
  History of smoking                    146            36.3                                           96                                            36.6        50    35.7   0.91
  Diabetes                              144            35.8                                           101                                           38.5        43    30.7   0.13
  Coronary heart disease                176            43.8                                           129                                           49.2        47    33.6   **0.003**
  Myocardial infarction                 88             21.9                                           67                                            25.6        21    15.0   **0.016**
  Hypertension                          350            87.1                                           230                                           87.8        120   85.7   0.64
  Renal dysfunction                     210            53.3                                           146                                           56.6        64    47.1   0.09
  Peripheral artery occlusive disease   93             23.1                                           68                                            26          25    17.9   0.08
  Cerebrovascular disease               59             14.7                                           34                                            13          25    17.9   0.24
  *Comorbidities at follow-up*                                                                                                                                                
  BMI≥30 Kg/m^2^                        145            38.7                                           96                                            39.3        49    37.4   0.70
  History of smoking                    147            36.6                                           97                                            37          50    35.7   0.80
  Diabetes                              161            40.0                                           115                                           43.9        46    32.9   **0.033**
  Coronary heart disease                228            56.9                                           159                                           60.9        69    49.3   **0.027**
  Myocardial infarction                 104            25.9                                           81                                            30.9        23    16.4   **0.002**
  Hypertension                          368            91.5                                           239                                           91.2        129   92.1   0.85
  Renal dysfunction                     281            69.9                                           188                                           71.8        93    66.4   0.30
  Peripheral artery occlusive disease   141            35.1                                           93                                            35.5        48    34.3   0.83
  Cerebrovascular disease               79             19.7                                           44                                            16.8        35    25.0   0.06
  History of statin-therapy             244            65.4                                           149                                           61.1        71    55.0   0.27

BMI, body mass index; *P* ~mean~, mean transaortic pressure gradient.

###### 

Clinical and laboratory characteristics.

                                                    Total cohort   Slow progression (*P* ~mean~ \< 5 mmHg/year)   Fast Progression (*P* ~mean~ ≥ 5  mmHg/year)   *P* value
  ------------------------------------------------- -------------- ---------------------------------------------- ---------------------------------------------- -------------
  Age at follow-up (years)                          77.7 ± 9.4     77.5 ± 9.8                                     78 ± 8.6                                       0.65
  Number of comorbidities                           3.1 ± 1.6      3.3 ± 1.5                                      2.9 ± 1.7                                      **0.036**
  Annual progression in AV *P* ~mean~ (mmHg/year)   4.5 ± 4.6      1.8 ± 1.6                                      9.5 ± 4.2                                      **\<0.001**
  Annual progression in AV *V* ~max~ (m/s/year)     0.08 ± 0.18    0.01 ± 0.12                                    0.22 ± 0.18                                    **\<0.001**
  Annual progression in AVA VTI (cm^2^/year)        −0.14 ± 0.14   −0.12 ± 0.13                                   −0.18 ± 0.16                                   **\<0.001**
  Baseline LVEF \<50% (n (%))                       69 (17.2%)     49 (18.7%)                                     20 (14.3%)                                     0.26
  LDL-cholesterol (mg/dl)                           103.8 ± 34.4   100 ± 32.6                                     110.8 ± 36.6                                   **0.005**
  HDL-cholesterol (mg/dl)                           52.0 ± 16.7    50.6 ± 16.3                                    54.7 ± 17.1                                    **0.025**
  HbA1c (%)                                         6.3 ± 1        6.34 ± 1                                       6.28 ± 1                                       0.65
  Hemoglobin (g/dl)                                 12.9 ± 3.8     12.7 ± 2.9                                     13.1 ± 5.1                                     0.32
  C-reactive protein (mg/dl)                        1.7 ± 2.4      1.9 ± 2.7                                      1.4 ± 1.9                                      **0.025**
  Creatinine (mg/dl)                                1.5 ± 1.2      1.5 ± 1.1                                      1.4 ± 1.3                                      0.72

AV, aortic valve; *P* ~mean~, mean transaortic pressure gradient; *V* ~max~, maximum velocity by continuous-wave Doppler; AVA VTI, aortic valve area calculated by the velocity time integral; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c.

###### 

Echocardiographic characteristics between baseline and follow-up.

                             Total cohort       Slow progression (*P* ~mean~ \< 5 mmHg/year)   Fast Progression (*P* ~mean~ ≥ 5 mmHg/year)   *P* value
  -------------------------- ------------------ ---------------------------------------------- --------------------------------------------- -------------
  *LVEDD (mm)*                                                                                                                                
  Baseline                   47.9 ± 8.6         48.4 ± 8.9                                     47.0 ± 7.9                                    0.11
  Follow-up                  47.86 ± 8.5        48.2 ± 8.9                                     47.2 ± 7.7                                    0.23
                                                                                                                                             
  *IVSd (mm)*                                                                                                                                 
  Baseline                   11.5 ± 2.2         11.5 ± 2.2                                     11.6 ± 2.2                                    0.58
  Follow-up                  11.4 ± 2.3         11.2 ± 2.5                                     11.9 ± 1.9                                    **0.001**
                                                                                                                                             
  *LVPWd (mm)*                                                                                                                                
  Baseline                   11.2 ± 2.0         11.2 ± 2.0                                     11.3 ± 2.0                                    0.43
  Follow-up                  11.1 ± 2.0         10.9 ± 2.0^*∗*^                                11.7 ± 1.8                                    **\<0.001**
                                                                                                                                             
  *LVEF (%)*                                                                                                                                  
  Baseline                   53.8 ± 11.5        52.8 ± 11.5                                    55.7 ± 11.2                                   **0.020**
  Follow-up                  51.4 ± 12.4^*∗*^   50.1 ± 13.0^*∗*^                               53.9 ± 10.7                                   **0.002**
                                                                                                                                             
  *LAD (mm)*                                                                                                                                  
  Baseline                   41.5 ± 6.6         41.4 ± 6.9                                     41.8 ± 6.0                                    0.62
  Follow-up                  42.7 ± 6.6^*∗*^    42.7 ± 7.0^*∗*^                                42.79 ± 5.9                                   0.86
                                                                                                                                             
  *AVA VTI (cm* ^*2*^)                                                                                                                        
  Baseline                   1.3 ± 0.5          1.4 ± 0.4                                      1.3 ± 0.5                                     0.09
  Follow-up                  0.9 ± 0.3^*∗*^     1.0 ± 0.2^*∗*^                                 0.8 ± 0.2^*∗*^                                **\<0.001**
                                                                                                                                             
  *AV V* ~*max*~ *(m/s)*                                                                                                                      
  Baseline                   3.1 ± 0.9          3.0 ± 0.9                                      3.2 ± 0.8                                     **0.03**
  Follow-up                  3.7 ± 0.9^*∗*^     3.4 ± 0.8^*∗*^                                 4.3 ± 0.7^*∗*^                                **\<0.001**
                                                                                                                                             
  *AV P* ~*max*~ *(mmHg)*                                                                                                                     
  Baseline                   40.9 ± 22.5        39.75 ± 23.3                                   43.2 ± 20.72                                  0.14
  Follow-up                  57.6 ± 25.9^*∗*^   47.4 ± 21.1^*∗*^                               76.6 ± 23.3^*∗*^                              **\<0.001**
                                                                                                                                             
  *AV P* ~*mean*~ *(mmHg)*                                                                                                                    
  Baseline                   25.0 ± 14.5        24.3 ± 15.1                                    26.3 ± 13.1                                   0.20
  Follow-up                  37.0 ± 17.5^*∗*^   29.8 ± 13.8^*∗*^                               50.3 ± 15.9^*∗*^                              **\<0.001**

^*∗*^ *P* \< 0.05 vs. baseline. LVEDD, left ventricular end-diastolic dimension; IVSd, intraventricular septum thickness; LVPWd, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; AVA VTI, aortic valve area calculated by the velocity time integral; AV, aortic valve; *P* ~max~, maximal transaortic pressure gradient; *P* ~mean~, mean transaortic pressure gradient.

###### 

Odds ratio of cardiac comorbidities and risk factors and laboratory parameters at baseline associated with fast *P* ~mean~ progression.

                                        Crude OR (95% CI)      *P* value   Age and sex adjusted OR (95% CI)   *P* value   Age, sex, and LVEF adjusted OR (95% CI)   *P* value
  ------------------------------------- ---------------------- ----------- ---------------------------------- ----------- ----------------------------------------- -----------
  Age                                   1.005 (0.983--1.028)   0.644       ---                                ---         ---                                       ---
  Male gender                           0.994 (0.656--1.505)   0.976       ---                                ---         ---                                       ---
  LVEF                                  1.022 (1.003--1.042)   **0.023**   1.023 (1.003--1.043)               **0.023**   ---                                       ---
  BMI ≥ 30 kg/m^2^                      1.194 (0.715--1.993)   0.498       ---                                ---         ---                                       ---
  History of smoking                    0.961 (0.627--1.473)   0.854       ---                                ---         ---                                       ---
  Diabetes                              0.707 (0.457--1.094)   0.119       ---                                ---         ---                                       ---
  Coronary heart disease                0.521 (0.340--0.798)   **0.003**   0.487 (0.312--0.760)               **0.002**   0.496 (0.317--0.777)                      **0.002**
  Myocardial infarction                 0.514 (0.299--0.882)   **0.016**   0.494 (0.285--0.856)               **0.012**   0.532 (0.304--0.931)                      **0.027**
  Hypertension                          0.835 (0.458--1.522)   0.556       ---                                ---         ---                                       ---
  Renal dysfunction                     0.682 (0.449--1.035)   0.072       0.655 (0.428--1.002)               0.051       0.692 (0.450--1.064)                      0.093
  Peripheral artery occlusive disease   0.620 (0.371--1.036)   0.068       0.609 (0.363--1.022)               0.061       0.610 (0.362--1.027)                      0.063
  Cerebrovascular disease               1.458 (0.830--2.560)   0.189       ---                                ---         ---                                       ---
  Number of comorbidities               0.869 (0.761--0.991)   **0.037**   0.852 (0.741--0.980)               **0.025**   0.863 (0.750--0.994)                      **0.041**
  LDL-cholesterol                       1.009 (1.002--1.016)   **0.009**   1.010 (1.003--1.017)               **0.005**   1.010 (1.003--1.017)                      **0.006**
  HDL-cholesterol                       1.015 (1.001--1.029)   **0.034**   1.015 (1.001--1.029)               **0.042**   1.014 (1.000--1.028)                      0.051
  HbA1c                                 0.969 (0.764--1.229)   0.793       ---                                ---         ---                                       ---
  Hemoglobin                            1.016 (0.985--1.047)   0.326       ---                                ---         ---                                       ---
  C-reactive protein                    0.952 (0.874--1.036)   0.254       ---                                ---         ---                                       ---
  Creatinine                            1.001 (0.799--1.253)   0.996       ---                                ---         ---                                       ---

*P* ~mean~, mean transaortic pressure gradient; OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c.

[^1]: Guest Editor: Frederik Trinkmann
